Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial

Post time 6 day(s) ago

journal：Journal of Clinical Oncology

Authors：Paul J. Brckelmann; Ina Bühnen; Julia Meissner; Karolin Trautmann-Grill; Peter Herhaus; Teresa V. Halbsguth; Valdete Schaub; Andrea Kerkhoff; Stephan Mathas; Matthias Bormann; Andreas Dickhut; Helen Kaul; Michael Fuchs; Carsten Kobe; Christian Baues; Peter Borchmann; Andreas Engert; Bastian von Tresckow

Published date：2023-2-20

DOI：10.1200/jco.22.02355

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.02355

Article link：https://doi.org/10.1200/jco.22.02355

Article Source：American Society of Clinical Oncology (ASCO)。I NEED THE FULL TEXT AND SUPPLEMENTARY ARTICLE

Remark：

Post time 6 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial